Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Canadian researchers design new cysteine protease inhibitors

Jan. 2, 1998

FDA deems Provigil approvable

Dec. 31, 1997

Potent and selective AMPA antagonist from Roche

Dec. 31, 1997

Scherer to develop Zydis ondansetron for Glaxo Wellcome

Dec. 30, 1997

New antipsychotics discovered at Duphar

Dec. 30, 1997

Pfizer claims NOS inhibitors for CNS and inflammatory disorders

Dec. 30, 1997

Merck & Co.'s newest D4 antagonists possess potent antipsychotic activity

Dec. 30, 1997

Suntory in-licenses new antidementia agent

Dec. 29, 1997

New AVP(4-9) analogue with beneficial effects on cognitive/memory deficits

Dec. 24, 1997

Mitsui presents new antipsychotic agent

Dec. 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...